CITIC Securities Co., Ltd.’s special verification opinions on the storage, management and actual use of funds raised by Kemei Diagnostic Technology Co., Ltd. in 2025
About CITIC Securities Co., Ltd.
Kemei Diagnostic Technology Co., Ltd.
Special verification opinions on the storage, management and actual use of raised funds in 2025
CITIC Securities Co., Ltd. (hereinafter referred to as "CITIC Securities" or the "Sponsor"), as the sponsor for the initial public offering of Kemei Diagnostics Technology Co., Ltd. (hereinafter referred to as "Komei Diagnostics" or the "Company"), in accordance with the "Regulatory Guidelines for Listed Companies No. 2 - Regulatory Requirements for the Management and Use of Funds Raised by Listed Companies", the "Self-Regulatory Guidelines for Companies Listed on the Shanghai Stock Exchange Science and Technology Innovation Board No. 1 - Standardized Operations", the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and other relevant regulations, CITIC Securities Co., Ltd. The storage and use of annual raised funds were specially verified. The verification results are as follows:
1. Basic situation of raised funds
(1) The actual amount of funds raised and the time when the funds will be received
With the approval of the China Securities Regulatory Commission's "Reply on the Registration of the Initial Public Offering of Shares of Kemei Diagnostic Technology Co., Ltd." (CSRC License [2021] No. 550), the company issued 41,000,000 RMB ordinary shares to the public for the first time, with a par value of RMB 1.00 per share, an issue price of RMB 7.15 per share, and a total amount of funds raised of RMB 293,150,000.00. The amount of various issuance expenses (excluding tax) is RMB 44,593,051.99, and the net amount of funds raised after deducting the issuance expenses is RMB 248,556,948.01.
ShineWing Certified Public Accountants LLP (Special General Partnership) verified the company's funding availability for this public issuance of new shares, and issued "Capital Verification Report" No. XYZH/2021BJAB10387 on April 2, 2021.
After the raised funds arrive, they have all been deposited in the special account for raised funds. In accordance with the requirements of the "Shanghai Stock Exchange's Self-Regulatory Supervision Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations", the company has signed the "Tripartite Supervision Agreement for the Special Account Storage of Raised Funds" and the "Four-Party Supervision Agreement for the Special Account Storage of Raised Funds" with the sponsor institution and the commercial bank where the raised funds are deposited.
(2) Use and balance of raised funds
As of December 31, 2025, the company's fundraising projects have used a total of 256.4209 million yuan of raised funds (excluding cash management of idle raised funds), and the raised funds have been used up. The details are as follows: Unit: 10,000 yuan
Item Amount
Total funds raised 29,315.00 Less: Issuance-related expenses 4,459.31 Net funds raised 24,855.69 Less: Cumulative amount of raised funds used (including the amount of upfront investment in replacement) 25,642.09 Including: New in vitro diagnostic reagent production base project 12,314.34 LiCA® reagent and supporting instrument R&D (laboratory) project 8,909.50 LiCA® reagent and key biological raw material R&D project 4,418.26 Less: The amount of taxes paid for issuance expenses 212.83 Less: The amount of temporarily idle raised funds used for cash management at the end of the period - Add: The net amount of interest income on raised funds minus handling fees 999.22
Balance of raised funds -
2. Management of raised funds
(1) Management system of raised funds
In order to standardize the management and use of raised funds and protect the rights and interests of investors, in accordance with the "Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules" and "Listed Company Supervision Guidelines No. 2 - Supervisory Requirements for the Management and Use of Raised Funds by Listed Companies", "Shanghai Stock Exchange Science and Technology Innovation Board Listed Companies Self-Discipline Supervision Guidelines No. 2" No. 1 - Standardized Operations" and other laws, regulations and normative documents, combined with the actual situation, the company formulated the "Measures for the Management of Raised Funds of Kemei Diagnostic Technology Co., Ltd." (hereinafter referred to as the "Measures for the Management of Raised Funds"), which made specific and clear provisions on the storage, use, management and supervision of raised funds, and strictly managed and used the raised funds in accordance with the provisions of the "Measures for the Management of Raised Funds".
(2) Supervision agreement on raised funds and storage of special accounts
In accordance with the provisions of the "Regulations on the Management of Raised Funds" and in combination with operational needs, the company and the sponsor CITIC Securities signed a "Tripartite Supervision Agreement" with the Beijing Zhongguancun Branch of Bank of Hangzhou Co., Ltd. and the Shanghai Branch of Ping An Bank Co., Ltd. respectively; the company, CITIC Securities and Ping An Bank Co., Ltd. Shanghai Branch respectively signed a "Tripartite Supervision Agreement" with the subsidiary Kemei Boyang Diagnostic Technology (Shanghai) Co., Ltd. (hereinafter referred to as "Kemei Boyang") and Kemei Diagnostic Technology (Suzhou) Co., Ltd. (hereinafter referred to as "Suzhou Kemei") signed the "Four-Party Supervision Agreement for the Special Account Storage of Raised Funds"; the company, CITIC Securities, China Construction Bank Co., Ltd. Suzhou High-tech Industrial Development Zone Branch and its subsidiary Suzhou Kemei signed the "Four-Party Supervision Agreement for the Special Account Storage of Raised Funds", which clarifies the rights and obligations of all parties. There are no major differences between the above-mentioned regulatory agreement and the Shanghai Stock Exchange's sample fund-raising regulatory agreement, and the company has strictly complied with it when using the raised funds.
As of December 31, 2025, the company's special account for funds raised from the initial public offering has no balance and has been closed.
3. Actual use of funds raised this year
(1) Comparison table of usage of raised funds
In 2025, for details of the company's actual usage, please refer to "Appendix 1 Usage Comparison Table of Raised Funds" in this verification opinion.
(2) Advance investment and replacement of raised funds
In 2025, the company will not use raised funds to replace upfront investment.
(3) Temporarily supplementing working capital with idle raised funds
In 2025, the company will not use idle raised funds to temporarily supplement working capital.
(4) Cash management and investment in related products of idle raised funds
The company held the third meeting of the second board of directors and the third meeting of the second board of supervisors on April 26, 2023, and reviewed and approved the "Proposal on the Company's Use of Idle Raised Funds for Cash Management" and agreed that the company's reasonable use limit shall not exceed RMB 100,000,000.00 on the premise that it will not affect the construction and use arrangements of the raised funds projects and effectively control risks. RMB (including the principal amount) of temporarily idle raised funds will be used for cash management and the purchase of capital-guaranteed products with high security and good liquidity (including but not limited to agreement deposits, structured deposits, time deposits, large certificates of deposit, notice deposits and other products). The usage period is valid for 12 months from the date of approval by the company's board of directors. Within the aforementioned limit and usage period, funds can be used on a rolling basis. The company's supervisory board and independent directors issued clear consent opinions on the above matters.
The company held the 10th meeting of the second board of directors and the ninth meeting of the second board of supervisors on April 29, 2024, and reviewed and approved the "Proposal on the Company's Use of Idle Raised Funds for Cash Management" and agreed that the company's reasonable use limit shall not exceed RMB 3,000 on the premise that it will not affect the construction and use arrangements of the raised funds projects and effectively control risks. Temporarily idle raised funds of RMB 10,000 (including the principal amount) will be used for cash management and the purchase of capital-guaranteed products with high security and good liquidity (including but not limited to agreement deposits, structured deposits, time deposits, large certificates of deposit, notice deposits and other products). The usage period is valid for 12 months from the date of approval by the company's board of directors. Within the aforementioned limit and usage period, funds can be used on a rolling basis. The company's supervisory board and sponsor issued clear consent opinions on the above matters.
As of December 31, 2025, the company had not used temporarily idle raised funds for cash management.
(5) Use of excess raised funds to permanently supplement working capital or return bank loans
In 2025, the company will not permanently replenish working capital or repay bank loans with excess raised funds.
(6) The use of excess raised funds for projects under construction and new projects (including acquisition of assets, etc.)
In 2025, the company will not use excess raised funds for projects under construction or new projects (including acquisition of assets, etc.).
(7) Usage of surplus raised funds
As of December 31, 2025, the company's raised funds have been used up, and there is no surplus of raised funds.
(8) Other uses of raised funds
In 2025, the company has no other use of raised funds.
4. Changes in the use of funds for investment projects with raised funds
In 2025, the company did not change the investment projects of raised funds.
5. Problems in the use and disclosure of raised funds
In 2025, the company has disclosed the use and management of raised funds in accordance with relevant regulations such as the "Regulatory Guidelines for Listed Companies No. 2 - Supervisory Requirements for the Management and Use of Funds Raised by Listed Companies", the "Self-Regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations" and other relevant regulations and the company's "Measures for the Management of Raised Funds". There are no violations in the management of raised funds.
- Conclusive opinions of the accounting firm’s assurance report on the deposit and use of the company’s annual raised funds
Rongcheng Accounting Firm (Special General Partnership) believes that Kemei Diagnostics' 2025 "Special Report on the Deposit, Management and Actual Use of Raised Funds" is prepared in all major aspects in accordance with the above-mentioned "Supervisory Rules for Raised Funds of Listed Companies" and the relevant regulations of the exchange, and fairly reflects the actual storage, management and use of the funds raised by Kemei Diagnostics in 2025.
- The concluding opinions of the special verification report issued by the sponsor on the deposit and use of the company’s annual raised funds
After verification, the sponsor believes that:
The deposit and use of funds raised by the company in 2025 complies with the "Guidelines for the Supervision of Listed Companies No. 2" No. - Supervisory Requirements for the Management and Use of Funds Raised by Listed Companies, "Shanghai Stock Exchange's Self-Regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations", "Shanghai Stock Exchange's Science and Technology Innovation Board Stock Listing Rules", the company's "Raised Funds Management Measures" and other relevant laws, regulations and provisions. The raised funds have been deposited in special accounts and used for special purposes. There is no disguised change of the use of raised funds and harm to the interests of shareholders, and there is no illegal use of raised funds.
(No text below)
Attachment 1:
Comparison table of usage of raised funds
Prepared by: Kemei Diagnostic Technology Co., Ltd. 2025 Unit: 10,000 yuan
Total funds raised 24,855.69
The total amount of raised funds invested during the reporting period 62.99The total amount of raised funds whose purpose was changed during the reporting period -
Cumulative total amount of raised funds changed in use -
The total amount of raised funds that have been invested 25,642.09 The cumulative proportion of the total raised funds that have been changed in use -
Has it changed? Cumulative as of the end of the period. As of the end of the period, the project has been achieved. The project is feasible.
Does this report meet the promised investment projects and over-raised projects? Raised capital commitments Adjusted total investment This report period investment The cumulative investment amount as of the end of the period and the total investment progress Whether the scheduled availability has been achieved during the period The total investment amount (1) of the expected capital investment (including part of the investment amount (1) The difference between the investment amount (2) The difference in the investment amount (%) (4) = Benefits of major changes on the date of use Benefits
Change) Amount (3) = (2)-(1) (2)/(1) Period Hua Xin Xin In vitro diagnostic reagent production May 2024
No 47,437.14 12,055.69 - 12,314.34 258.64 102.15 Not applicable Not applicable No Production base project Month
LiCA® reagents and supporting instruments
2024
Device research and development (laboratory) item No 10,699.87 8,600.00 - 8,909.50 309.50 103.60 Not applicable Not applicable No
November
Head
LiCA® Reagents and Key Biotechnology 2025 4
No 5,332.81 4,200.00 62.99 4,418.26 218.26 105.20 Not applicable Not applicable No Material R&D project Month
Total 63,469.82 24,855.69 62.99 25,642.09 786.39 Not applicable
Failure to meet the planned progress or forecast. In view of the impact of the COVID-19 epidemic, market environment, the company's actual operating conditions, R&D project progress and other factors, the progress of the LiCA® reagent and supporting instrument R&D (laboratory) project, LiCA® reagent and key biometric income and the reasons for the raw material R&D project have lagged behind the plan. Regarding the postponement of fundraising projects, the company held the ninth meeting of the second board of directors and the eighth meeting of the second board of supervisors on March 26, 2024, and reviewed and approved the "Proposal on the Extension of Some Fund-raising Projects" (divided into specific fundraising projects).
Project feasibility occurs significantly
Not applicable
Description of changing circumstances
Raise funds to invest in projects first
For details, please refer to "3. Actual Use of Raised Funds This Year" for "(2) Preliminary Investment and Replacement of Raised Investment Projects" and "Preliminary Investment and Replacement"
Use idle raised funds temporarily
For details, please refer to "(3) Temporary replenishment of working capital with idle raised funds" in "3. Actual use of raised funds during the year" to replenish working capital.
Carry out idle raised funds
Cash management, investment-related For details, please refer to (4) Cash management of idle raised funds and investment-related products in "3. Actual use of raised funds this year". Product information
Replenish permanently with super-raised funds
Working capital or return to the bank. For details, please refer to "3. Actual use of raised funds this year" (5) Use of excess raised funds to permanently replenish working capital or return bank loans" for loan status.
The amount of remaining funds raised
Not applicable
and causes
Other uses of raised funds
For details, please refer to "(8) Other Use of Raised Funds" in "III. Actual Use of Raised Funds This Year"
Note 1: “The total amount of raised funds invested” includes the “accumulated amount invested” after the raised funds are received and the actual amount of advance investment that has been replaced. Note 2: The "committed investment amount as of the end of the period" is determined based on the latest disclosed investment plan for raised funds.
(This page has no text, but is the signature page of the "Special Verification Opinions of CITIC Securities Co., Ltd. on the Deposit, Management and Actual Use of Funds Raised by Kemei Diagnostic Technology Co., Ltd. in 2025")
Sponsor representative: _______________ _______________
Shao Caijie Jiao Yanyan
CITIC Securities Co., Ltd.
year month day